Hyderabad-based Aurobindo Pharma announced that it had received final approval from the US Food and Drug Administration (USFDA) for Perindopril Erbumine tablets meant for treatment of hypertension.
The multiple doses ( 2mg, 4 mg and 8 mg) tablets are generic equivalent of Solvay Pharmaceuticals Aceon tablets. The product will be launched shortly, the company stated in a press release on Thursday.
According to an Aurobindo spokesperson, the market potential for the product is about $ 25-30 million. Aurobindo has USFDA approvals for 109 abbreviated new drug applications (ANDAs). Of these 81 ANDAs got final approval and 28 received tentative approvals.
Aurobindo's scrip on the BSE was trading at Rs 805.4, down 0.87 per cent from the previous day's close of Rs 812.45.
Content Guide
